

S13 Table. The distribution of treatment responses in a subset of patients who receiving ICI therapy according to cancer types

Cancer type	Best overall response				Clinical benefit			Total
	CR/PR	SD	PD	Unknown	DCB	NDB	Unknown	
Carcinoma of other site	3	3	3	3	6	3	3	12
Cervical cancer	3	5	6	0	8	6	0	14
Colorectal cancer	8	5	2	1	13	2	1	16
Endometrial cancer	0	0	0	1	0	0	1	1
Esophageal carcinoma	0	2	1	0	2	1	0	3
Gallbladder cancer	1	1	0	0	2	0	0	2
Gastric cancer	2	0	6	1	2	6	1	9
Liver cancer	0	4	3	3	4	3	3	10
Lung cancer	6	8	14	6	14	14	6	34
Melanoma	12	35	50	10	47	50	10	107
Ovarian cancer	1	1	0	1	2	0	1	3
Pancreatic carcinoma	0	2	4	1	2	4	1	7
Sarcoma	0	2	2	0	2	2	0	4
Total	36	68	91	27	104	91	27	222

Carcinoma of other site indicates kidney cancer (n=2), urothelium carcinoma (n=3), Nasopharyngeal carcinoma (n=1), scrotum carcinoma (n=1), lymphoma (n=1), neuroblastoma (n=1), and unknown (n=3). CR, complete response; DCB, durable clinical benefit; ICIs, immune checkpoint inhibitors; NDB, no durable benefit; PD, progression disease; PR, partial response; SD, stable disease.